Authors: Domingo C,Niedrig M,
Address: Robert Koch Institut, Centre for Biological Safety, Berlin, Germany.
Journal: Expert Opin Drug Saf.
Publication: 2009 Mar;8(2):211-21. doi: 10.1517/14740330902808086 .
abstractBACKGROUND:
yellow fever, a mosquito-borne viral haemorrhagic fever, is one of the most lethal viral diseases. At present, an efficient vaccine for prevention is available, but may cause serious adverse events.
METHODS:
The authors review the up-to-date knowledge for serious adverse events of the yellow fever vaccine (YFSAE): hypersensitivity reactions, neurotropic and viscerotropic syndromes.
RESULTS:
The incidence of YFSAE has been associated with increasing age and thymus disorders, but still a number of cases with any risk factor remain unexplained, which suggests that other factors, from the virus or the host, could be involved in the appearance of these postvaccinal adverse events.
CONCLUSIONS:
YFSAE are uncommon but must be prevented. Further research on the virus-host immune response is needed to have a better understanding of the basis for the appearance of these severe side effects after vaccination. Vaccination should be limited to people with a true risk of exposure to wild-type yellow fever virus.
Related ArticlesReview [Yellow fever].Przegl Epidemiol. 2004
Review [Yellow fever].
Wiercińska-Drapało A. Przegl Epidemiol. 2004; 58 Suppl 1:101-5.
Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX.Vaccine. 2004
Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX.
Kitchener S. Vaccine. 2004 Jun 2; 22(17-18):2103-5.
Review Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.Vaccine. 2011
Review Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.
Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T. Vaccine. 2011 Jun 20; 29(28):4544-55. Epub 2011 May 5.
Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases.Lancet. 2001
Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases.
Vasconcelos PF, Luna EJ, Galler R, Silva LJ, Coimbra TL, Barros VL, Monath TP, Rodigues SG, Laval C, Costa ZG, et al. Lancet. 2001 Jul 14; 358(9276):91-7.
[Yellow fever vaccination: update on rare and severe adverse effects].Med Mal Infect. 2009
[Yellow fever vaccination: update on rare and severe adverse effects].
Receveur MC, Bruyand M, Pistone T, Malvy D. Med Mal Infect. 2009 Apr; 39(4):234-41. Epub 2009 Jan 23.
Human leukocyte antigen (HLA) class I restricted epitope discovery in yellow fewer and dengue viruses: importance of HLA binding strength.PLoS One. 2011
Human leukocyte antigen (HLA) class I restricted epitope discovery in yellow fewer and dengue viruses: importance of HLA binding strength.
Lund O, Nascimento EJ, Maciel M Jr, Nielsen M, Larsen MV, Lundegaard C, Harndahl M, Lamberth K, Buus S, Salmon J, et al. PLoS One. 2011; 6(10):e26494. Epub 2011 Oct 19.
Arboviral etiologies of acute febrile illnesses in Western South America, 2000-2007.PLoS Negl Trop Dis. 2010
Arboviral etiologies of acute febrile illnesses in Western South America, 2000-2007.
Forshey BM, Guevara C, Laguna-Torres VA, Cespedes M, Vargas J, Gianella A, Vallejo E, Madrid C, Aguayo N, Gotuzzo E, et al. PLoS Negl Trop Dis. 2010 Aug 10; 4(8):e787. Epub 2010 Aug 10.
Review Comparative pathogenesis and systems biology for biodefense virus vaccine development.J Biomed Biotechnol. 2010
Review Comparative pathogenesis and systems biology for biodefense virus vaccine development.
Bowick GC, Barrett AD. J Biomed Biotechnol. 2010; 2010:236528. Epub 2010 Jun 6.
To
top
•
Home
Show
map | Diseases | Vaccination
| Chronic disease | Medicine
| Pregnancy
| Heat & Sunburn | Cold | Security
| Useful tips | Faq
| News
TraveldoctorOnline 2001 •
Disclaimer • webmaster
